Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million milestone payment from Pierre Fabre Laboratories THOUSAND OAKS, Calif. / Nov 12, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA),... Read More

Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial... Read More

THOUSAND OAKS, Calif / Sep 03, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder and managing... Read More

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred substantially all operational activities and associated costs related to tab-cel to Pierre Fabre Laboratories Atara has resumed its evaluation of strategic options Approval of BLA would unlock a $40 Million milestone payment from Pierre Fabre Laboratories, materially extending cash runway THOUSAND OAKS, Calif. / Aug... Read More

First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immunosuppression Tabelecleucel has... Read More

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD THOUSAND OAKS, Calif. / Jul 24, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and... Read More

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after failure of standard therapy NCT04554914 also open for enrollment to patients with EBV-associated... Read More

Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories THOUSAND OAKS, Calif. / Jul 14, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging... Read More

THOUSAND OAKS, Calif. / May 16, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the... Read More

Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives Atara has entered into an underwriting agreement for an offering... Read More

THOUSAND OAKS, Calif. / May 15, 2025 / Business Wire / Atara Biotherapeutics, Inc . (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded... Read More

FDA lifts clinical hold enabling resumption of clinical trials FDA has granted a Type A Meeting to discuss path forward for BLA THOUSAND OAKS, Calif. / May 05, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today... Read More

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources Strategic review by financial advisor ongoing THOUSAND OAKS, Calif. / Mar 07, 2025 /... Read More

THOUSAND OAKS, Calif. / Feb 07, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 1,350 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) THOUSAND OAKS, Calif. / Jan 21, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today... Read More

Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics License Application (BLA), and the FDA did not request any new clinical studies to support approval Atara remains committed to working with the FDA, Pierre Fabre Laboratories, and the third-party manufacturer to bring... Read More

THOUSAND OAKS, Calif. / Nov 27, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7 th Annual... Read More

THOUSAND OAKS, Calif. / Nov 13, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024... Read More

Tab-cel ® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin’s Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus Nephritis and Extrarenal Systemic Lupus Erythematosus Study Initiation Expected by End of Year; Initial Clinical Data Expected Mid-2025 Cash Runway Into 2027 Enables Key Pipeline Readouts THOUSAND OAKS, Calif. / Nov 12, 2024 / Business... Read More

THOUSAND OAKS, Calif. / Nov 05, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara... Read More

THOUSAND OAKS, Calif. / Oct 04, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,500 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Sep 06, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,700 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Sep 04, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will present at the H.C.... Read More

Led by Existing Top Institutional Investors With Participation From a New Strategic Investor Well Positioned To Execute on Tab-cel ® U.S. BLA Approval and Advancement of ATA3219 Further Strengthens Balance Sheet With Cash Runway Into 2027 Enabling Key Pipeline Readouts THOUSAND OAKS, Calif. / Sep 03, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel... Read More

Tab-cel ® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025 ATA3219 Lupus Nephritis and Severe Systemic Lupus Erythematosus Study Initiation Expected Q4 2024; Initial Clinical Data Expected Mid-2025 Enrolling ATA3219 Non-Hodgkin’s Lymphoma Study; Initial Clinical Data Expected Q1 2025 Effective September 9, 2024, Pascal Touchon To Assume Role of Chairman of the Board of Directors of Atara;... Read More

THOUSAND OAKS, Calif. / Aug 07, 2024 / Business Wire / Atara Biotherapeutics, Inc . (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief... Read More

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if Approved by FDA THOUSAND OAKS, Calif. / Jul 17, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,... Read More

THOUSAND OAKS, Calif. / Jul 05, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 2,200 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Jul 03, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual... Read More

Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD THOUSAND OAKS, Calif. / Jun 21, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Ebvallo TM... Read More

THOUSAND OAKS, Calif. / Jun 17, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the... Read More

THOUSAND OAKS, Calif. / Jun 07, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Jun 05, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief... Read More

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared With Autologous Benchmark CD19 CAR T Cells Results Support Clinical Evaluation of ATA3219, Including Initiation of Phase 1 Study in Lupus Nephritis and Severe... Read More

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, with Potential for Additional $60 Million Milestone Upon FDA Approval THOUSAND OAKS, Calif. / May 20, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a... Read More

Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned for Q4 2024, with Initial Clinical Data Expected in H2 2025 Enrolling ATA3219 Non-Hodgkin’s Lymphoma Study, with Initial Clinical Data Expected in Q4 2024... Read More

THOUSAND OAKS, Calif. / May 03, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Apr 05, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024 Cash Runway Into 2027 Enables Key Pipeline Readouts THOUSAND OAKS, Calif. / Mar 28, 2024 /... Read More

Second IND Clearance for ATA3219 Following Non-Hodgkin’s Lymphoma (NHL) and First in an Autoimmune Disease Indication Initial Clinical Data in NHL Anticipated in H2 2024 and for Lupus Nephritis in H1 2025 THOUSAND OAKS, Calif. / Feb 29, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop... Read More

THOUSAND OAKS, Calif. / Feb 28, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the... Read More

ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN) ATA3219 Is Designed to Combine the Natural Biology of Unedited T Cells and the Benefits of an Allogeneic CAR T Approach With Preclinical Data Demonstrating Potential Efficacy in LN Second IND Submission for ATA3219, Following Non-Hodgkin’s Lymphoma (NHL) IND Clearance Received in Q3 2023 THOUSAND... Read More

First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File THOUSAND OAKS, Calif. & CASTRES, France / Jan 31, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,... Read More

THOUSAND OAKS, Calif. / Jan 08, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727... Read More

Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel ® Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE Study Expansion of Next-gen Allogeneic CAR-T Portfolio to Autoimmune Disease ATA3219 IND in Lupus Nephritis Planned in Q1 2024 Focused Operational Activities and Associated Strategic Restructuring Extends Cash Runway into 2027 THOUSAND... Read More

THOUSAND OAKS, Calif. / Jan 04, 2024 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare... Read More

THOUSAND OAKS, Calif. / Dec 20, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel ® or EBVALLO TM... Read More

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or Alloreactivity Data Supports Advancement Into IND-Enabling Studies THOUSAND OAKS, Calif. / Dec 11, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic... Read More

THOUSAND OAKS, Calif. / Dec 01, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees. These awards were... Read More

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate (ORR) in 18 EBV+ CNS PTLD Patients, Including First Line PTLD Setting and Promising Long-Term Survival THOUSAND OAKS, Calif. / Nov 29, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell... Read More

THOUSAND OAKS, Calif. / Nov 22, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6 th Annual... Read More

THOUSAND OAKS, Calif. / Nov 10, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare... Read More

Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and Planned Expense Reductions Expected to Extend Cash Runway Beyond Q3 2025 Allogeneic CAR-T Portfolio Advancing with Several Catalysts Anticipated in the Next 18 Months THOUSAND OAKS, Calif. / Nov 08, 2023 / Business Wire / Atara... Read More

Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel ® , including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic... Read More

THOUSAND OAKS, Calif. / Oct 06, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 56,750 restricted stock units of Atara’s common stock to four newly hired employees. These awards were... Read More

THOUSAND OAKS, Calif. / Sep 19, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel ® ) in the U.S. Following productive... Read More

THOUSAND OAKS, Calif. / Sep 01, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / Aug 31, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a Cell Therapies in Autoimmune panel... Read More

Discussions With FDA Progressing on Potential BLA Submission for Tab-cel® With Meeting Scheduled To Resolve Remaining Topic of Comparability ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication Will Now Occur in Early November To Include the Last Patient Visits From More Than 90 Patients IND Cleared for Atara's First Allogeneic CAR T, ATA3219, in Relapsed/Refractory B-Cell NHL THOUSAND OAKS, Calif. / Aug 08, 2023 /... Read More

THOUSAND OAKS, Calif. / Aug 04, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 72,000 restricted stock units of Atara’s common stock to two newly hired employees. These awards were... Read More

THOUSAND OAKS, Calif. / Aug 01, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About... Read More

THOUSAND OAKS, Calif. / Jul 31, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate at the Canaccord Genuity 43rd Annual Growth... Read More

THOUSAND OAKS, Calif. / Jul 07, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 116,550 restricted stock units of Atara’s common stock to five newly hired employee. These awards were... Read More

THOUSAND OAKS, Calif. / Jun 07, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs... Read More

Real-World Results Demonstrate Objective Response Rate (ORR) of 67% in 24 EBV+ PTLD Patients 91% Overall Survival (OS) at One Year for Patients Responding to Tab-cel Compared to 34% for Non-Responders Tab-cel Safety Profile Consistent with Phase 3 ALLELE Study Findings THOUSAND OAKS, Calif. / Jun 05, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel... Read More

THOUSAND OAKS, Calif. / Jun 02, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

First Patients Treated in Europe with EBVALLO TM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions with FDA Progressing ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 ATA3219 IND Filing Anticipated End of Q2 2023 THOUSAND OAKS, Calif. / May 08, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel... Read More

THOUSAND OAKS, Calif. / May 05, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 6,250 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by... Read More

THOUSAND OAKS, Calif. / May 01, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023. About Atara... Read More

THOUSAND OAKS, Calif. / Mar 31, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 93,950 restricted stock units of Atara’s common stock to three newly hired employees. These awards were... Read More

THOUSAND OAKS, Calif. / Mar 03, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 62,350 restricted stock units of Atara’s common stock to six newly hired employees. These awards were... Read More

THOUSAND OAKS, Calif. / Mar 01, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the... Read More

THOUSAND OAKS, Calif. / Feb 08, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for... Read More

CASTRES, France & THOUSAND OAKS, Calif. / Feb 08, 2023 / Business Wire / Pierre Fabre and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO ™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre. From today, Pierre... Read More

THOUSAND OAKS, Calif. / Feb 06, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February... Read More

THOUSAND OAKS, Calif. / Feb 03, 2023 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 36,750 restricted stock units of Atara’s common stock to three newly hired employees and stock options to... Read More

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common... Read More

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST /... Read More

HealthCare Royalty Receives Specified Milestones and Royalties for Ebvallo TM in Europe in Exchange for Upfront Cash Payment to Atara Non-Dilutive Funding Further Extends Atara’s Cash Runway Incremental to $40 Million of Existing Milestones from Pierre Fabre Following Ebvallo TM Marketing Authorization Approval and Filing for Application Transfer Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,... Read More

Only Approved Therapy for EU Patients with Rare and Potentially Deadly Cancer Facing Median Survival of Only a Few Months Represents First Approval of an Allogeneic T-Cell Immunotherapy Globally Pierre Fabre to Lead Commercialization and Distribution Activities in Europe THOUSAND OAKS, Calif. & CASTRES, France--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European... Read More

Phase 3 ALLELE Study Shows 51.2% Objective Response Rate (ORR) in 43 EBV+ PTLD Patients Median Duration of Response (DOR) of 23.0 Months Median Overall Survival of 18.4 Months with Patients Who Responded Having Longer Survival Than Non-Responders THOUSAND OAKS, Calif.--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV)... Read More